Product Description
a human IgG1kappa anti-CCL2 mAb (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24928772/)
Mechanisms of Action: CCL2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Centocor
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis|Prostate Cancer
Phase 1: Hypertension|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00537368 |
CR013699 | P1 |
Completed |
Hypertension |
None |
2019-03-21 |
Treatments |
|
NCT01204996 |
CR016462 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
2024-11-27 |
Primary Endpoints |
|
2008-001281-86 |
2008-001281-86 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2012-08-14 |
2022-03-12 |
Treatments |
|
NCT00786201 |
CR015235 | P2 |
Completed |
Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis |
2012-01-01 |
2019-03-18 |
||
2009-011251-48 |
2009-011251-48 | P2 |
Completed |
Prostate Cancer |
2011-07-06 |
2022-03-13 |
Treatments |
|
NCT00992186 |
CR015907 | P2 |
Completed |
Prostate Cancer |
2011-07-01 |
2019-03-19 |
Treatments |
|
2009-011250-17 |
2009-011250-17 | P2 |
Completed |
Unknown |
2010-07-14 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|